These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 31262668)

  • 1. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
    Bhutani D; Leng S; Lentzsch S
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and management of systemic light chain AL amyloidosis.
    Bhutani D; Lentzsch S
    Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis.
    Van Doren L; Lentzsch S
    Acta Haematol; 2020; 143(4):373-380. PubMed ID: 32526750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis.
    Wang J; Li J; Zhong L
    Blood Rev; 2024 Jul; 66():101207. PubMed ID: 38692939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
    Badar T; D'Souza A; Hari P
    F1000Res; 2018; 7():. PubMed ID: 30228867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis.
    Vaxman I; Gertz M
    Acta Haematol; 2019; 141(2):93-106. PubMed ID: 30650422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
    Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
    J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis.
    Godara A; Palladini G
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1145-1159. PubMed ID: 33099430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daratumumab for the treatment of AL amyloidosis.
    Sidiqi MH; Gertz MA
    Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs for the treatment of light chain amyloidosis.
    Chakraborty R; Lentzsch S
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):299-317. PubMed ID: 32731778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supportive Care for Patients with Systemic Light Chain Amyloidosis.
    Wong SW; Fogaren T
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1177-1191. PubMed ID: 33099432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Approaches for the Management of AL Amyloidosis.
    Joseph NS; Kaufman JL
    Curr Hematol Malig Rep; 2018 Jun; 13(3):212-219. PubMed ID: 29951831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits.
    Popkova T; Hajek R; Jelinek T
    Br J Haematol; 2020 Apr; 189(2):228-238. PubMed ID: 32072615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New and developing therapies for AL amyloidosis.
    Zumbo G; Sadeghi-Alavijeh O; Hawkins PN; Fontana M
    Expert Opin Pharmacother; 2017 Feb; 18(2):139-149. PubMed ID: 28002971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis and Staging of AL Amyloidosis.
    Dittrich T; Kimmich C; Hegenbart U; Schönland SO
    Acta Haematol; 2020; 143(4):388-400. PubMed ID: 32570242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supportive Care in AL Amyloidosis.
    Cibeira MT; Ortiz-Pérez JT; Quintana LF; Fernádez de Larrea C; Tovar N; Bladé J
    Acta Haematol; 2020; 143(4):335-342. PubMed ID: 32235118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis.
    Del Giudice ML; Galimberti S; Buda G
    Hematol Oncol; 2024 May; 42(3):e3270. PubMed ID: 38590272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
    Vaxman I; Dispenzieri A; Muchtar E; Gertz M
    Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.